tiprankstipranks
Trending News
More News >
Chimerix Hold Rating: Acquisition by Jazz Pharmaceuticals and Uncertain Clinical Prospects Justify Caution
PremiumRatingsChimerix Hold Rating: Acquisition by Jazz Pharmaceuticals and Uncertain Clinical Prospects Justify Caution
4M ago
Chimerix reports Q4 EPS (25c), consensus (28c)
Premium
The Fly
Chimerix reports Q4 EPS (25c), consensus (28c)
4M ago
Chimerix Hold Rating: Financial Constraints and Revised EPS Outlook Influence Cautious Recommendation
Premium
Ratings
Chimerix Hold Rating: Financial Constraints and Revised EPS Outlook Influence Cautious Recommendation
4M ago
Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential
PremiumRatingsStrategic Acquisition and NDA Submission Boost Chimerix’s Market Potential
4M ago
Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval
Premium
Ratings
Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval
4M ago
Chimerix downgraded to Hold from Buy at Jefferies
Premium
The Fly
Chimerix downgraded to Hold from Buy at Jefferies
4M ago
Chimerix Merges with Jazz Pharmaceuticals in $935M Deal
PremiumCompany AnnouncementsChimerix Merges with Jazz Pharmaceuticals in $935M Deal
4M ago
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash
Premium
The Fly
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash
4M ago
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M
Premium
The Fly
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100